The latest news:

• National Cancer Institute designates UCLA brain cancer program a site of research excellence         I am proud to say that I am the patient advocate on the board for this program!  This is a brilliant group of researchers who deserve this recognition and will put the grant money to great use to speed up the search for the cure!
  



• Patients Who Used Optune® More Than 90 Percent of the Time Had the Greatest Chance of Survival in Novocure’s EF-14 Trial: A Median Survival of 24.9 Months from Randomization and a Five-Year Survival of 29.3 Percent         A 29.3% 5 year survival - on a large number of patients in a randomized phase 3 trial is very impressive. This shows a dose-response effect, which proves that the concept actually works.  When comparing the median survival, remember that this is from the time that the patients were randomized, not from diagnosis - the difference is almost 4 months. This means that the median survival is almost 29 months, which is a big step forward!
  



• Toca 5 Trial is now open!         I went to an impressive presentation by Tocagen today at the SNO meeting!  They have a few long term survivors who not only are survivors, but have been able to return to work and lead productive lives.  The phase 3 trial opened yesterday.
  



• GBM Heroes Honored By CURE         Thanks to Cure Magazine, Novocure, Dr Sumrall, as well as my wife and kids - without whom I wouldn't have been able to do this!
  

BrainTumor Co-Payment Assistance Program Status:

• CLOSED to new applicants